Nuvectis Pharma (NVCT) Change in Accured Expenses (2021 - 2026)

Nuvectis Pharma has reported Change in Accured Expenses for 6 years, with the latest figure at -$460000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 1940.0% year-over-year to -$460000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $866000.0 (up 128.5% YoY) and the FY2025 annual result came in at $1.4 million, up 217.88% from the prior year.
• Change in Accured Expenses slipped to -$460000.0 in Q1 2026 per NVCT's latest filing, from $2.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.1 million in Q4 2025 and troughed at -$863000.0 in Q2 2025.
• A 5-year average of $190411.8 and a median of $154000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses jumped 1271.7% in 2022, then tumbled 1940.0% in 2026.
• Over 5 years, Change in Accured Expenses stood at -$305000.0 in 2022, then soared by 184.26% to $257000.0 in 2023, then soared by 75.1% to $450000.0 in 2024, then jumped by 372.44% to $2.1 million in 2025, then tumbled by 121.64% to -$460000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$460000.0, $2.1 million, and $63000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.